These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27443391)

  • 1. Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease.
    Hendrikx T; Watzenböck ML; Walenbergh SM; Amir S; Gruber S; Kozma MO; Grabsch HI; Koek GH; Pierik MJ; Staufer K; Trauner M; Kalhan SC; Jonkers D; Hofker MH; Binder CJ; Shiri-Sverdlov R
    BMC Med; 2016 Jul; 14(1):107. PubMed ID: 27443391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease.
    Karrar A; Stepanova M; Alaparthi L; Lingam S; Younoszai Z; Zheng L; Malik KS; Younossi E; Monge F; Hunt SL; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2015 May; 30(5):900-8. PubMed ID: 25469790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD).
    Bruzzì S; Sutti S; Giudici G; Burlone ME; Ramavath NN; Toscani A; Bozzola C; Schneider P; Morello E; Parola M; Pirisi M; Albano E
    Free Radic Biol Med; 2018 Aug; 124():249-259. PubMed ID: 29920340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial.
    Capoulade R; Chan KL; Mathieu P; Bossé Y; Dumesnil JG; Tam JW; Teo KK; Yang X; Witztum JL; Arsenault BJ; Després JP; Pibarot P; Tsimikas S
    Atherosclerosis; 2017 May; 260():1-7. PubMed ID: 28319871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2014 May; 60(5):1055-62. PubMed ID: 24445215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of immunoglobulins in an adult population and their relationship with nonalcoholic fatty liver disease.
    Sun SM; Wang YY; Zhang Q; Liu L; Meng G; Yao ZX; Wu HM; Xia Y; Bao X; Gu YQ; Wang HL; Shi HB; Xu HY; Wang X; Zhou M; Jiao HL; Jia QY; Wang BM; Niu KJ
    J Dig Dis; 2018 Aug; 19(8):498-507. PubMed ID: 29989347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural antibodies to oxidation-specific epitopes: innate immune response and venous thromboembolic disease.
    Eichinger S; Kyrle PA; Kammer M; Eischer L; Ozsvar Kozma M; Binder CJ
    J Thromb Haemost; 2018 Jan; 16(1):31-35. PubMed ID: 29045005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction.
    Taleb A; Willeit P; Amir S; Perkmann T; Kozma MO; Watzenböck ML; Binder CJ; Witztum JL; Tsimikas S
    J Lipid Res; 2023 Jun; 64(6):100391. PubMed ID: 37211249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum IgA, IgG, and IgM antibodies directed against acetaldehyde-derived epitopes: relationship to liver disease severity and alcohol consumption.
    Viitala K; Israel Y; Blake JE; Niemelä O
    Hepatology; 1997 Jun; 25(6):1418-24. PubMed ID: 9185762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls.
    Heebøll S; Poulsen MK; Ornstrup MJ; Kjær TN; Pedersen SB; Nielsen S; Grønbæk H; Handberg A
    Int J Obes (Lond); 2017 Feb; 41(2):262-267. PubMed ID: 27916988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
    Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of serum IgG, IgA and IgM levels as indicators of hepatic fibrosis in patients with chronic hepatitis C infection].
    Ortarık Z; Toyran A; Sen S; Mart Kömürcü SZ; Güvener E
    Mikrobiyol Bul; 2011 Apr; 45(2):296-305. PubMed ID: 21644073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum immunoglobulins (IgG, IgA, IgM) in chronic hepatitis C. A comparison with non-cirrhotic alcoholic liver disease.
    Gonzàlez-Quintela A; Alende MR; Gamallo R; Gonzàlez-Gil P; López-Ben S; Tomé S; Otero E; Torre JA
    Hepatogastroenterology; 2003; 50(54):2121-6. PubMed ID: 14696478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidation-specific epitopes are major targets of innate immunity in atherothrombosis.
    Bartolini Gritti B; Binder CJ
    Hamostaseologie; 2016 May; 36(2):89-96. PubMed ID: 25682990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease.
    Croci I; Byrne NM; Choquette S; Hills AP; Chachay VS; Clouston AD; O'Moore-Sullivan TM; Macdonald GA; Prins JB; Hickman IJ
    Gut; 2013 Nov; 62(11):1625-33. PubMed ID: 23077135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different aspects of immunological profile in patients with Non-Alcoholic Fatty liver disease.
    Osman HA; Tag-Adeen M; Abdelaal UM; Elgezawy E; Nasif KA; Nafady A
    Acta Gastroenterol Belg; 2024; 87(2):274-281. PubMed ID: 39210759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.